Scalable, High-Density Expansion of Human Mesenchymal Stem Cells on Microcarriers Using the Bach Impeller in Stirred-Tank Reactors
- PMID: 40678872
- PMCID: PMC12417783
- DOI: 10.1002/bit.70025
Scalable, High-Density Expansion of Human Mesenchymal Stem Cells on Microcarriers Using the Bach Impeller in Stirred-Tank Reactors
Abstract
This paper describes the results of process developmental experiments to achieve higher cell densities in the manufacturing of hMSCs using the novel Bach impeller in a stirred-tank bioreactor. Engineering experiments have previously shown that the Bach impeller represents an efficient mixing device that suspends particles in fluids at low power inputs. To assess the impeller during biological experiments, the growth performance of Wharton Jelly (WJ)-hMSCs in a 1 L STR equipped with the Bach impeller was evaluated at a variety of culture conditions. The cells attached to Cytodex 1 microcarriers at a concentration of 5.6 g/L and were cultured for 5-7 days. The growth phase was carried out at varying impeller speeds = 75, 115, and 150 rpm. Cell growth was additionally evaluated at a microcarrier concentration of 11.2 g/L Cytodex 1. Here, a maximum cell density of up to 1.7 × 106 cells/mL and cell viability > 90% was achieved within 5 culture days, which is amongst the highest cell densities ever attained for a hMSC batch culture. Critical cell quality attributes of the WJ-hMSCs were assessed upon completion of the growth phase, that is, FACS to identify stem cell surface markers, tri-lineage differentiation, and capacity of the cells to form colonies. In addition, informed by the previously described engineering characterization, the 1 L process at = 75 rpm was scaled up to the 5 L scale, where WJ-hMSCs were again confirmed to have retained the relevant cell quality attributes. The reported findings are important to determine the design space to which scale-ups to even larger tank sizes can adhere.
Keywords: bioprocessing; engineering characterization; mesenchymal stem cells; microcarriers; stirred‐tank reactors.
© 2025 The Author(s). Biotechnology and Bioengineering published by Wiley Periodicals LLC.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
References
-
- Alici, E. , and Blomberg P.. 2010. “GMP Facilities for Manufacturing of Advanced Therapy Medicinal Products for Clinical Trials: An Overview for Clinical Researchers.” Current Gene Therapy 10, no. 6: 508–515. - PubMed
-
- Cantarero‐Rivera, F. , D'Souza D. H., Dhar M., and Chen J.. 2024. “Characterization of the Dynamic Viscosity of Cell Cultures and Its Effect on Mixing Performance in a Spinner Flask Bioreactor.” Biochemical Engineering Journal 212: 109523.
-
- Charalambidou, A. D. , Wyrobnik T. A., Micheletti M., and Ducci A.. 2024. “Investigation of the Impact of Probes and Internals on Power and Flow in Stirred Tank Reactors.” Chemical Engineering Science 286: 119683.
-
- Cheatham, L. A. , Noldner P., Ressler B., and Kurtzberg J.. 2019. “Optimization of Human Umbilical Cord‐Derived Mesenchymal Stem Cell Growth and Expansion Using a Closed‐System Hollow Fiber Bioreactor.” Stem Cells Translational Medicine 8, no. S1: S16.
-
- Chen, A. K. L. , Reuveny S., and Oh S. K. W.. 2013. “Application of Human Mesenchymal and Pluripotent Stem Cell Microcarrier Cultures in Cellular Therapy: Achievements and Future Direction.” Biotechnology Advances 31, no. 7: 1032–1046. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous
